PT  - JOURNAL ARTICLE
AU  - ISHIYAMA, YUDAI
AU  - KONDO, TSUNENORI
AU  - NEMOTO, YUKI
AU  - KOBARI, YUKI
AU  - ISHIHARA, HIROKI
AU  - TACHIBANA, HIDEKAZU
AU  - YOSHIDA, KAZUHIKO
AU  - HASHIMOTO, YASUNOBU
AU  - TAKAGI, TOSHIO
AU  - IIZUKA, JUNPEI
AU  - TANABE, KAZUNARI
TI  - Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy
AID  - 10.21873/anticanres.14922
DP  - 2021 Mar 01
TA  - Anticancer Research
PG  - 1607--1614
VI  - 41
IP  - 3
4099  - http://ar.iiarjournals.org/content/41/3/1607.short
4100  - http://ar.iiarjournals.org/content/41/3/1607.full
SO  - Anticancer Res2021 Mar 01; 41
AB  - Background/Aim: We investigated the prognostic nutritional index (PNI), comprised of lymphocytes and albumin, as a potential prognosticator of metastatic urothelial carcinoma (mUC) patients receiving pembrolizumab. Patients and Methods: Sixty-five patients were retrospectively enrolled and classified as low (<40) and high (≥40) based on pretreatment PNI. Progression-free survival (PFS), overall survival (OS) and response rates were evaluated. Results: In the low PNI group, significantly shorter PFS and OS were observed. PNI was shown to be an independent predictor of PFS and OS in the multivariate analysis. C-index for both PFS and OS improved with the addition of PNI to the model described in the KEYNOTE-045 study. Significantly more patients experienced initial disease progression in the low PNI group. Conclusion: PNI is a useful predictor of prognosis and disease progression in mUC patients receiving pembrolizumab.